The Sarcopenia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Sarcopenia: An Overview
Sarcopenia is a condition that is characterized by loss of muscle mass, muscle strength, and functional muscle impairment with aging. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases.
The etiology of sarcopenia is a constellation of factors involving the aging neuromuscular machinery (motor unit number and efficiency, muscle architecture and orientation, fiber type distribution), reduced anabolic hormone levels, muscle disuse, and inflammation, driven by environmental, genetic, and behavioral factors.
Sarcopenia Market Key Facts
In a study conducted by Yamaguchi et. al. (2020) on elderly patients with diabetes from Japan and Taiwan, Sarcopenia was found in 10.6% of Japan and 11.1% in Taiwan.
In the study conducted by Chang et. al. (2020), Sarcopenia prevalence, determined using the AWGS-recommended algorithm, was 40.3% and 41.3% in men and women, respectively. The overall prevalence of sarcopenia was 41.0% by the AWGS-recommended algorithm.
In a study conducted by Kitamura et. al. (2020) on Japanese residents of the age group 65 years and above, the prevalence of sarcopenia was approximately 14%. Overall, 11.5% of men and 16.7% of women were affected by the disease in Japan.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Sarcopenia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Sarcopenia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Sarcopenia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Sarcopenia Epidemiology, Segmented as –
Prevalent Cases of Sarcopenia in Japan (2019–2032)
Gender-Specific Prevalent Cases of Sarcopenia in Japan (2019–2032)
Diagnosed and Treatable Cases of Sarcopenia in Japan (2019–2032)
Sarcopenia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Sarcopenia market or expected to be launched during the study period. The analysis covers the Sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Sarcopenia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Sarcopenia Market Will Evolve and Grow by 2032 @
Sarcopenia Therapeutics Analysis
There are currently no approved drug treatments for sarcopenia. The condition requires a multimodal management approach combining a nutritional strategy targeting nutrient quality and intake, exercise, and anti-inflammatory and anabolic medications. Treatments have focused mostly on extrinsic approaches such as exercise and diet, but recent scientific advances have brought greater attention to additional treatment options. Research is underway to identify therapeutic targets and develop a curative therapy for the treatment of sarcopenia. But, the current sarcopenia pipeline is poor, with very few industry-funded trials.
Several major pharma and biotech companies are developing therapies for Sarcopenia. Currently, Biophytis is leading the therapeutics market with its Sarcopenia drug candidates in the most advanced stage of clinical development.
Leading Players in the Sarcopenia Therapeutics Market Include
Rubedo Life Sciences
And Many Others
Sarcopenia Emerging and Marketed Drugs Covered in the Report Include:
Sarconeos (BIO101): Biophytis
MYMD-1: MyMD Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Sarcopenia Competitive Intelligence Analysis
4. Sarcopenia Market Overview at a Glance
5. Sarcopenia Disease Background and Overview
6. Sarcopenia Patient Journey
7. Sarcopenia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Sarcopenia Treatment Algorithm, Current Treatment, and Medical Practices
9. Sarcopenia Unmet Needs
10. Key Endpoints of Sarcopenia Treatment
11. Sarcopenia Marketed Products
12. Sarcopenia Emerging Drugs and Latest Therapeutic Advances
13. Sarcopenia Seven Major Market Analysis
14. Attribute Analysis
15. Sarcopenia Market Outlook (In US, EU5, and Japan)
16. Sarcopenia Access and Reimbursement Overview
17. KOL Views on the Sarcopenia Market
18. Sarcopenia Market Drivers
19. Sarcopenia Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports by DelveInsight
Secondary Hyperparathyroidism Market
“Secondary Hyperparathyroidism Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Secondary Hyperparathyroidism market.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States